Gilead Sciences buying Forty Seven for $4.9 billion

Gilead Sciences is buying the cancer treatment company Forty Seven in a deal valued at approximately $4.9 billion.

Gilead, based in Foster City, California, will pay $95.50 for each Forty Seven Inc. share.

Gilead said Monday that the transaction will strengthen its immuno-oncology research and development portfolio with the addition of of Forty Seven Inc.'s investigational lead product candidate, magrolimab, which is in for the treatment of several cancers.

Forty Seven's stock soared more than 60% before the market open. Gilead rose 1.2%.

The deal is targeted to close in the .

Explore further

Gilead faces lawsuit over hepatitis C drug pricing

© 2020 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission.

Citation: Gilead Sciences buying Forty Seven for $4.9 billion (2020, March 2) retrieved 3 August 2021 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments